J&J MAY NOT MEET U.S. COVID-19 VACCINE SUPPLY TARGET BY SPRING

J&J MAY NOT MEET U.S. COVID-19 VACCINE SUPPLY TARGET BY SPRING

Johnson & Johnson (NYSE:JNJ) is facing unexpected delays in the manufacturing of its coronavirus vaccine and may not be able to supply the doses it promised the federal government by spring, the New York Times reported on Wednesday.

U.S. federal officials have been told that J&J has fallen as much as two months behind the original production schedule and will not catch up until the end of April, when it was supposed to have delivered more than 60 million doses, citing people familiar with the situation.

The company and the U.S. Department of Health and Human Services did not immediately respond.

Earlier this week, J&J’s chief executive officer said the company was on track to have close to a billion COVID-19 vaccine doses by 2021-end.

On technical fronts J&J’s RSI stood at 62.12 and currently stock is trading below 5 days MA and above 20 and 50 days moving averages. So, BUY position can be taken with following target and stoploss:

TRADE SIGNAL – : J&J’s – BUY: 158.12, TARGET: 160.81, STOPLOSS : 157.32

About Author

Related posts

Bitcoin prices

Bitcoin’s outlook for the quarter is bright, Miami conference to be majorly influential.

Bitcoin prices are up 0.14% at $46662.51 on early Tuesday trades. In Q1, Bitcoin prices witnessed a bearish trend, closing near its opening for the quarter, declining around 5%. Many analysts believe that Bitcoin is poised to break out and soar after a bout of profit-taking. The second quarter,...

Read More
Top 5 Stock

Top 5 Stock To Watch out Today March 31, 2022

1.MOODY’S:- Moody’s  said on Thursday it has withdrawn all ratings on Russia and its rated Russian sub-sovereign entities. The company said it had decided to withdraw the ratings for its own business reasons. Last week, Moody’s had announced its intention to withdraw its credit ratings on the entities, following similar...

Read More
Top 5 Stock

Top 5 Stock To Watch out Today March 30, 2022

1.UBS:-UBS spent 3.81 billion Swiss francs ($4.10 billion) repurchasing its shares equivalent to 6.49% of its share capital in its 2021 buyback, the Swiss bank said on Wednesday. The cancellation of most of the repurchased shares will be proposed at the bank’s upcoming shareholder meeting on April 6. The...

Read More